Jean-Frèdèric Paulsen

Part of Ferring Ventures, FinVector Oy is a Finnish biopharmaceutical company that specializes in manufacturing viral-based gene therapy products. The private company is based in Kuopio, Finland, and has extensive experience in cgmp manufacturing. FinVector employs hundreds of highly qualified professionals from over 40 different countries and works on cutting-edge biopharmaceuticals. It has invested in building state-of-the-art gmp facilities for viral vector platforms. The company was founded in 1993 by Seppo Ylä-Herttuala, and the CEO is Giuseppe Carloni.

Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark.

Ferring International Center SA develops, manufactures and markets products in the fields of urology, gynaecology and obstetrics. It also specializes in the fields of gastroenterology and endocrinology. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland.

Ferring Holding SA operates as a holding company with interests in pharmaceutical products. The company was founded in 2000 and is headquartered in Saint-Prex, Switzerland.